Jefferies Group Analysts Decrease Earnings Estimates for Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Jefferies Group reduced their Q3 2017 earnings per share (EPS) estimates for shares of Gilead Sciences in a note issued to investors on Wednesday. Jefferies Group analyst M. Yee now expects that the biopharmaceutical company will post earnings of $1.86 per share for the quarter, down from their previous forecast of $1.90. Jefferies Group has a “Positive” rating on the stock. Jefferies Group also issued estimates for Gilead Sciences’ Q4 2017 earnings at $1.66 EPS.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.08 EPS. TRADEMARK VIOLATION WARNING: “Jefferies Group Analysts Decrease Earnings Estimates for Gilead Sciences, Inc. (GILD)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/05/jefferies-group-analysts-decrease-earnings-estimates-for-gilead-sciences-inc-gild.html.
A number of other analysts have also issued reports on the company. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Thursday, August 31st. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price target on shares of Gilead Sciences in a research note on Thursday, August 31st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $85.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target on the stock in a research note on Monday, June 26th. Ten investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $85.36.
Gilead Sciences (GILD) opened at 82.42 on Thursday. The stock’s 50 day moving average price is $80.40 and its 200-day moving average price is $71.48. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a market capitalization of $107.63 billion, a P/E ratio of 8.95 and a beta of 1.14.
Hedge funds and other institutional investors have recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its holdings in Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC increased its holdings in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. increased its holdings in Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. purchased a new stake in Gilead Sciences during the 1st quarter worth about $143,000. Institutional investors own 73.99% of the company’s stock.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 486,819 shares of company stock worth $39,298,919. 1.30% of the stock is owned by company insiders.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.52%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.